ConductScience.org, home
Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy
API referenceFor AI assistants

Trial · NCT01103323

Results by group22

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 22

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Overall SurvivalRegorafenib (Stivarga, BAY73-4506)+BSC19695% Confidence Interval 178 to 222Days
Overall SurvivalPlacebo+BSC15195% Confidence Interval 134 to 177Days
Progression-free Survival (Based on Investigator's Assessment)Regorafenib (Stivarga, BAY73-4506)+BSC5995% Confidence Interval 57 to 65Days
Progression-free Survival (Based on Investigator's Assessment)Placebo+BSC5295% Confidence Interval 51 to 53Days
Objective Tumor ResponseRegorafenib (Stivarga, BAY73-4506)+BSC1.0Percentage of participants
Objective Tumor ResponsePlacebo+BSC0.4Percentage of participants
Disease ControlRegorafenib (Stivarga, BAY73-4506)+BSC41.0Percentage of participants
Disease ControlPlacebo+BSC14.9Percentage of participants
Tumor ResponseRegorafenib (Stivarga, BAY73-4506)+BSCComplete Response (CR)0Percentage of participants
Tumor ResponsePlacebo+BSCComplete Response (CR)0Percentage of participants
Tumor ResponseRegorafenib (Stivarga, BAY73-4506)+BSCPartial Response (PR)1.0Percentage of participants
Tumor ResponsePlacebo+BSCPartial Response (PR)0.4Percentage of participants
Tumor ResponseRegorafenib (Stivarga, BAY73-4506)+BSCStable Disease (SD)42.8Percentage of participants
Tumor ResponsePlacebo+BSCStable Disease (SD)14.5Percentage of participants
Tumor ResponseRegorafenib (Stivarga, BAY73-4506)+BSCProgressive Disease (PD)49.5Percentage of participants
Tumor ResponsePlacebo+BSCProgressive Disease (PD)80.0Percentage of participants
Tumor ResponseRegorafenib (Stivarga, BAY73-4506)+BSCNon CR/Non PD0.8Percentage of participants
Tumor ResponsePlacebo+BSCNon CR/Non PD0.4Percentage of participants
Tumor ResponseRegorafenib (Stivarga, BAY73-4506)+BSCNot applicable0.2Percentage of participants
Tumor ResponsePlacebo+BSCNot applicable0Percentage of participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01103323/results

API referenceFor AI assistants